Vaccine Efficacy Monitoring

Vaccine Efficacy Monitoring: Get a more comprehensive picture

VEM-XP makes use of Althea’s patented XP technology, a highly-multiplexed, quantitative reverse transcriptase-PCR strategy that incorporates the use of gene-specific and universal primers to lock gene ratios during the amplification process. This cost efficient method, which yields data on 20-35 genes per reaction, enables researchers to extend their gene expression studies to large number of samples, increasing the statistical power of gene expression information. The technology is highly complementary to microarray analysis and enables researchers to further exploit their microarray discoveries.

The AltheaDx Process: Signature Discovery, Biomarker Identification and Diagnostic Tool Development

Genes chosen are key biomarkers for monitoring cellular and humoral responses to vaccines. A critical biomarker probe set was developed and consolidated into a single assay that allows monitoring of responses in preclinical models and/or clinical patients.

• Predictive Drug Response
• Cellular Immune Response
  Type 1 - Maximizes the killing efficacy of the macrophages and in the proliferation of cytotoxic CD8+ T cells
• Humoral Immune Response
  Type 2 - Humoral Immune system. Stimulates B Cells into
  proliferation, to induce B-cell antibody class
  switching and to increase antibody production
• Comprehensive Efficacy Picture

FEATURES:

• Monitor PBMC gene expression
  response to antigen challenge
• 22 Immunologically relevant genes covering cellular and humoral immune reponses
• Single PCR multiplexing using
  Beckman GeXP system
• Directly integrates into standard ELISpot protocols.
• Predictive Drug Respones
• Cellular Immune Response
• Humoral Immune Response Disease
• Comprehensive Efficacy Picture